Literature DB >> 10559918

p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells.

H Sutterlüty1, E Chatelain, A Marti, C Wirbelauer, M Senften, U Müller, W Krek.   

Abstract

The F-box protein p45SKP2 is the substrate-targeting subunit of the ubiquitin-protein ligase SCFSKP2 and is frequently overexpressed in transformed cells. Here we report that expression of p45SKP2 in untransformed fibroblasts activates DNA synthesis in cells that would otherwise growth-arrest. Expression of p45SKP2 in quiescent fibroblasts promotes p27Kip1 degradation, allows the generation of cyclin-A-dependent kinase activity and induces S phase. Coexpression of a degradation-resistant p27Kip1 mutant suppresses p45SKP2-induced cyclin-A-kinase activation and S-phase entry. We propose that p45SKP2 is important in the progression from quiescence to S phase and that the ability of p45SKP2 to promote p27Kip1 degradation is a key aspect of its S-phase-inducing function. In transformed cells, p45SKP2 may contribute to deregulated initiation of DNA replication by interfering with p27Kip1 function.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10559918     DOI: 10.1038/12027

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  238 in total

1.  Cyclin E-mediated elimination of p27 requires its interaction with the nuclear pore-associated protein mNPAP60.

Authors:  D Müller; K Thieke; A Bürgin; A Dickmanns; M Eilers
Journal:  EMBO J       Date:  2000-05-15       Impact factor: 11.598

2.  ATF4 degradation relies on a phosphorylation-dependent interaction with the SCF(betaTrCP) ubiquitin ligase.

Authors:  I Lassot; E Ségéral; C Berlioz-Torrent; H Durand; L Groussin; T Hai; R Benarous; F Margottin-Goguet
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

Review 3.  SCF ubiquitin ligase-targeted therapies.

Authors:  Jeffrey R Skaar; Julia K Pagan; Michele Pagano
Journal:  Nat Rev Drug Discov       Date:  2014-11-14       Impact factor: 84.694

4.  FoxM1 involvement in astrocyte proliferation after spinal cord injury in rats.

Authors:  Shuangwei Zhang; Honglin Teng; Qiulei Ding; Jinpeng Fan; Wanying Shi; Yan Zhou; Chunwu Zhang
Journal:  J Mol Neurosci       Date:  2013-02-06       Impact factor: 3.444

5.  Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT.

Authors:  Amer M Mirza; Stephan Gysin; Nisar Malek; Kei-ichi Nakayama; James M Roberts; Martin McMahon
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

6.  A novel thyroid hormone receptor isoform, TRβ2-46, promotes SKP2 expression and retinoblastoma cell proliferation.

Authors:  Zhengke Li; Dong-Lai Qi; Hardeep P Singh; Yue Zou; Binghui Shen; David Cobrinik
Journal:  J Biol Chem       Date:  2019-01-14       Impact factor: 5.157

7.  Cyclin-dependent kinase 4 overexpression is mostly independent of gene amplification and constitutes an independent prognosticator for nasopharyngeal carcinoma.

Authors:  Tzu-Ju Chen; Sung-Wei Lee; Li-Ching Lin; Ching-Yih Lin; Kwang-Yu Chang; Chien-Feng Li
Journal:  Tumour Biol       Date:  2014-04-27

8.  SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential.

Authors:  Yu-Feng Tian; Tzu-Ju Chen; Ching-Yih Lin; Li-Tzong Chen; Li-Ching Lin; Chung-Hsi Hsing; Sung-Wei Lee; Ming-Jen Sheu; Hao-Hsien Lee; Yow-Ling Shiue; Hsuan-Ying Huang; Hsin-Yi Pan; Chien-Feng Li; Shang-Hung Chen
Journal:  Tumour Biol       Date:  2013-01-18

9.  Spy1 interacts with p27Kip1 to allow G1/S progression.

Authors:  Lisa A Porter; Monica Kong-Beltran; Daniel J Donoghue
Journal:  Mol Biol Cell       Date:  2003-07-11       Impact factor: 4.138

10.  Role of Cks1 overexpression in oral squamous cell carcinomas: cooperation with Skp2 in promoting p27 degradation.

Authors:  Shojiro Kitajima; Yasusei Kudo; Ikuko Ogawa; Tarig Bashir; Masae Kitagawa; Mutsumi Miyauchi; Michele Pagano; Takashi Takata
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.